Showing 2291-2300 of 4065 results for "".
Improving Sleep and Mental Health in Patients with CKD-aP
https://reachmd.com/programs/cme/improving-sleep-and-mental-health-in-patients-with-ckd-ap/36301/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Incorporating Guideline-Recommended Targeted Therapies Into R/R AML Management
https://reachmd.com/programs/cme/incorporating-guideline-recommended-targeted-therapies-into-rr-aml-management/36181/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Rethinking Schizophrenia Treatment Through Muscarinic Modulation
https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/Learn expert insights on muscarinic antipsychotics in schizophrenia, including mechanisms, safety, and switching considerations.QoL Matters: Brain Stem Stimulation in Patients With Unipolar Depression
https://reachmd.com/programs/cme/qol-matters-brain-stem-stimulation-in-patients-with-unipolar-depression/35796/Tune in to learn about using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) & treatment-resistant depression (TRD).IgAN SOC: Strengths and Limits
https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Mechanism-Based Targeting: Why APRIL Matters in IgAN
https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.APRIL Uncovered: An Upstream Driver in IgAN
https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.